Neurosense Therapeutics is trading 11.1% lower at $2.73, with no verified company-specific catalyst linked to the decline.
- The company announced an October 19 U.S. patent application covering potential PrimeC use in traumatic brain injury; available coverage does not connect the filing to the selloff.
- Shares are falling despite positive major-index readings in the supplied market context, which does not clearly explain the move.
- Intraday volume information was not provided.